Teva Pharmaceutical Industries (TEVA) Cash & Equivalents (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Cash & Equivalents for 18 consecutive years, with $3.7 billion the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents rose 120.45% year-over-year to $3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 billion (up 120.45% YoY) and the FY2025 annual result came in at $3.6 billion, up 7.76% from the prior year.
• Cash & Equivalents improved to $3.7 billion in Q1 2026 per TEVA's latest filing, from $3.6 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for TEVA reached as high as $3.7 billion in Q1 2026 and fell as low as $1.7 billion in Q1 2025.
• A 5-year average of $2.6 billion and a median of $2.3 billion in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents tumbled 43.26% — and 2026, when it surged 120.45%.
• Year by year, Cash & Equivalents stood at $2.8 billion in 2022, then rose by 15.17% to $3.2 billion in 2023, then grew by 2.29% to $3.3 billion in 2024, then climbed by 7.76% to $3.6 billion in 2025, then advanced by 5.2% to $3.7 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.7 billion, $3.6 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.